(Q40295958)

19 September 2017

title

What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines (English)

1 reference

19 September 2017

1 reference

3

S A Plotkin

1 reference

19 September 2017

Nicolas Burdin

1

1 reference

19 September 2017

L K Handy

series ordinal

2

1 reference

19 September 2017

publication date

13 March 2017

1 reference

Cold Spring Harbor Perspectives in Biology

19 September 2017

published in

1 reference

Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Asymptomatic transmission and the resurgence of Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Poor memory B cell generation contributes to non-protective responses to DTaP vaccine antigens in otitis-prone children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis infection and vaccination induces Th1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Roads to the development of improved pertussis vaccines paved by immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Transcriptome signature for dampened Th2 dominance in acellular pertussis vaccine-induced CD4(+) T cell responses through TLR4 ligation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Adult pertussis in the pre- and post-vaccine eras: lifelong vaccine-induced immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Identification of pertussis-specific effector memory T cells in preschool children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

The pertussis enigma: reconciling epidemiology, immunology and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

c-di-GMP enhances protective innate immunity in a murine model of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

The recurrence of whooping cough: possible implications for assessment of vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Memory T follicular helper CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vacci

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Evolution of Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Clinical practice. Pertussis--not just for kids

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Immunity to the respiratory pathogen Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Transiently increased IgE responses in infants and pre-schoolers receiving only acellular Diphtheria-Pertussis-Tetanus (DTaP) vaccines compared to those initially receiving at least one dose of cellular vaccine (DTwP) - Immunological curiosity or ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Systematic review of the effects of pertussis vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis: Microbiology, Disease, Treatment, and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Licensed pertussis vaccines in the United States. History and current state

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Waning protection after fifth dose of acellular pertussis vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Waning Tdap Effectiveness in Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Priming with whole-cell versus acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis vaccine performance in an epidemic year-Oregon, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis: acellular, whole-cell, new vaccines, what to choose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Live attenuated vaccines against pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Sustained Transmission of Pertussis in Vaccinated, 1-5-Year-Old Children in a Preschool, Florida, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Duration of pertussis immunity after DTaP immunization: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussi

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Possible options for new pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Differential expression of alpha 4 integrins on effector memory T helper cells during Bordetella infections. Delayed responses in Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Complex correlates of protection after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

21 January 2018

The pertussis problem.

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis: pertussis control strategies and the options for improving current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

The acellular pertussis vaccine trials: an interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Development of improved pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Sources of Infant Pertussis Infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis Across the Globe: Recent Epidemiologic Trends From 2000-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Waning immunity to pertussis following 5 doses of DTaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Waning and aging of cellular immunity to Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

The baboon model of pertussis: effective use and lessons for pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Maternal and neonatal vaccination protects newborn baboons from pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Estimating the duration of pertussis immunity using epidemiological signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Duration of immunity against pertussis after natural infection or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

California pertussis epidemic, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

The immunoregulatory role of CD4+FoxP3+CD25−regulatory T cells in lungs of mice infected withBordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029454

Pertussis in adults: frequency of transmission after household exposure

21 January 2018

1 reference

12 December 2020

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001

1 reference

12 December 2020

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

1 reference

12 December 2020

Laboratory-confirmed reinfections with Bordetella pertussis

1 reference

12 December 2020

Duration of protection after first dose of acellular pertussis vaccine in infants

1 reference

12 December 2020

Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection

1 reference

12 December 2020

Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines

1 reference

12 December 2020

Why do pertussis vaccines fail?

1 reference

12 December 2020

Pertussis vaccines: WHO position paper - September 2015

1 reference

12 December 2020

Bordetella pertussis Infection in 2-Month-Old Infants Promotes Type 1 T Cell Responses

1 reference

12 December 2020

Immune responses to pertussis vaccines and disease

1 reference

12 December 2020

Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children

1 reference

12 December 2020

A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

1 reference

12 December 2020

Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model

1 reference

12 December 2020

The effectiveness of whole-cell pertussis vaccines

1 reference

12 December 2020

Pertussis control: time for something new?

1 reference

12 December 2020

A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine

1 reference

12 December 2020

Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents

1 reference

12 December 2020

Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate

1 reference

12 December 2020

Outer membrane vesicles as acellular vaccine against pertussis

1 reference

12 December 2020

Comparison of 13 acellular pertussis vaccines: adverse reactions.

1 reference

12 December 2020

Increase of pertussis incidence in 2010 to 2012 after 12 years of low circulation in Spain.

1 reference

12 December 2020

Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination

1 reference

12 December 2020

Persistence of T-cell immune response induced by two acellular pertussis vaccines in children five years after primary vaccination

1 reference

12 December 2020

Comparison of 13 acellular pertussis vaccines: overview and serologic response

1 reference

12 December 2020

Cell‐Mediated Immunity and Antibody Responses toBordetella pertussisAntigens in Children with a History of Pertussis Infection and in Recipients of an Acellular Pertussis Vaccine

1 reference

12 December 2020

10.1101/CSHPERSPECT.A029454

Identifiers

DOI

1 reference

19 September 2017

0 references

1 reference